Urtica comp. gel for prevention and therapy of radiation dermatitis An interdisciplinary, interprofessional phase II randomized controlled trial in patients with breast cancer

Urtica comp. gel for prevention and therapy of radiation dermatitis An interdisciplinary, interprofessional phase II randomized controlled trial in patients with breast cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Urtica comp. gel for prevention and therapy of radiation dermatitis An interdisciplinary, interprofessional phase II randomized controlled trial in patients with breast cancer Jodie Freeman, Nannen Timo, Sester Susanne, Wolf Ursula This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4710982/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Purpose: Radiation dermatitis (RD) is one of the most common side effects of radiotherapy for breast cancer and affects 90 % of patients. Skin lesions bear a marked risk of infection and have a profound impact on the patient’s quality of life, due to pain and discomfort. This can cause interruption to radiotherapy, resulting in inadequate disease treatment. The aim was to test if Urtica comp. gel reduces the incidence and severity of RD, reduce the need for additional therapy, pain, and improve the quality of life. Methods: A randomised open-label phase II study compared Urtica comp. gel with the standard of care, Excipial-Hydrolotion. Patients were assessed at baseline, at weekly assessments and up to 6 weeks after radiotherapy. Results: A total of 30 patients were randomly assigned and included. There was no statistically significant difference in maximum acute RD between Urtica comp. gel and Excipial-Hydrolotion. However, Urtica comp. gel significantly reduced the need for rescue care with only 31 % of the 13 patients needing rescue care compared to 69 % using Excipial-Hydrolotion. A chi-square test of independence found that the relationship was highly significant, X 2 (1, N =28) = 5.073 , p = 0.02 . Results also showed a trend for reduced pain (Cohen's d = 0.74, p = 0.09) and itchiness (not significant Cohen's d = 0.57, p=0.16) on the Visual Analog Scale (VAS) for patients receiving Urtica comp. gel. In addition, patients using Urtica comp. gel rated the appearance of their RD as significantly better than patients receiving Excipial-Hydrolotion (p < 0.02, p < 0.03, p < 0.02) in week 3, 4 and 5 respectively. There were no major differences between groups on skin-related quality of life. Conclusion: This study yielded promising results and found that Urtica comp. gel was statistically more effective than standard of care in reducing the need for rescue care in patients undergoing radiotherapy. Patients also rate the appearance of their RD as significantly better when using Urtica comp and scored lower pain and itchiness on the VAS. These results highlight that Urtica comp. gel may be an effective treatment option against RD. This should be further tested in a larger clinical trial. Trial Registration NCT03494205 Full Text Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4710982","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":333914374,"identity":"e6521564-728a-4be5-8462-9738d918bab7","order_by":0,"name":"Jodie Freeman","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA/0lEQVRIie3PsYqDMBjA8a8IdvloH0CorxARbuy9SkWoSzwKXTrcUBB0kZu9t/AodFYCPoOgg72hs1DoFa4cl9gOpZC6dsh/Cl/yIwmASvWEDdZAMrEYri+DCZ+FYjHrJZhdBnYv4RG4JQ6/TX9ItCj4ylrYAhos/y7fay+tgrBpYfomfVhcLPIEKsDR3LVpsffTOo+sBNyllCSUMOTkFfHFoDrz09IJDYRMvFBOzuIWHP/80j/mEUHOfQQ6grrmh2zWEXhExF9iUglhG/4Hsz5LJ7Ji4kqJFQWb9rSqJoja7kCPzByV3r45raZy0m0QwLs5kZznmfItlUqlUl37B1OPXZ1EJxpzAAAAAElFTkSuQmCC","orcid":"","institution":"University of Bern","correspondingAuthor":true,"prefix":"","firstName":"Jodie","middleName":"","lastName":"Freeman","suffix":""},{"id":333914375,"identity":"f638b080-2423-4dfe-849b-60450cf675ce","order_by":1,"name":"Nannen Timo","email":"","orcid":"","institution":"University Hospital of Bern","correspondingAuthor":false,"prefix":"","firstName":"Nannen","middleName":"","lastName":"Timo","suffix":""},{"id":333914376,"identity":"02ce41e2-3e8c-482b-9314-c4358396f442","order_by":2,"name":"Sester Susanne","email":"","orcid":"","institution":"University Hospital of Bern","correspondingAuthor":false,"prefix":"","firstName":"Sester","middleName":"","lastName":"Susanne","suffix":""},{"id":333914377,"identity":"1db81c1c-bb92-4690-acac-b6bc1c51fa2e","order_by":3,"name":"Wolf Ursula","email":"","orcid":"","institution":"University of Bern","correspondingAuthor":false,"prefix":"","firstName":"Wolf","middleName":"","lastName":"Ursula","suffix":""}],"badges":[],"createdAt":"2024-07-09 09:47:09","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4710982/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4710982/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":68754874,"identity":"e84e364b-e7aa-42c8-8c8b-0ee5b07b3dc2","added_by":"auto","created_at":"2024-11-11 16:46:55","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":361036,"visible":true,"origin":"","legend":"","description":"","filename":"V1FinalManuscriptRadDermatitisJF0907.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4710982/v1_covered_1eb88688-be01-4857-94e2-4a8c9a617c91.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Urtica comp. gel for prevention and therapy of radiation dermatitis An interdisciplinary, interprofessional phase II randomized controlled trial in patients with breast cancer","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-4710982/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4710982/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003ePurpose: \u003c/strong\u003eRadiation dermatitis (RD) is one of the most common side effects of radiotherapy for breast cancer and affects 90 % of patients. Skin lesions bear a marked risk of infection and have a profound impact on the patient’s quality of life, due to pain and discomfort. This can cause interruption to radiotherapy, resulting in inadequate disease treatment.\u003c/p\u003e\n\u003cp\u003eThe aim was to test if Urtica comp. gel reduces the incidence and severity of RD, reduce the need for additional therapy, pain, and improve the quality of life.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods:\u0026nbsp;\u003c/strong\u003eA randomised open-label phase II study compared Urtica comp. gel with the standard of care, Excipial-Hydrolotion. Patients were assessed at baseline, at weekly assessments and up to 6 weeks after radiotherapy.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults:\u0026nbsp;\u003c/strong\u003eA total of 30 patients were randomly assigned and included. There was no statistically significant difference in maximum acute RD between Urtica comp. gel and Excipial-Hydrolotion. However, Urtica comp. gel significantly reduced the need for rescue care with only 31 % of the 13 patients needing rescue care compared to 69 % using Excipial-Hydrolotion. A chi-square test of independence found that the relationship was highly significant, \u003cem\u003eX\u003c/em\u003e\u003csup\u003e2 \u003c/sup\u003e(1, \u003cem\u003eN \u003c/em\u003e=28) = 5.073\u003cem\u003e, p = 0.02\u003c/em\u003e. Results also showed a trend for reduced pain (Cohen's d = 0.74, p = 0.09) and itchiness (not significant Cohen's d = 0.57, p=0.16) on the Visual Analog Scale (VAS) for patients receiving Urtica comp. gel. In addition, patients using Urtica comp. gel rated the appearance of their RD as significantly better than patients receiving Excipial-Hydrolotion (p \u0026lt; 0.02, p \u0026lt; 0.03, p \u0026lt; 0.02) in week 3, 4 and 5 respectively. There were no major differences between groups on skin-related quality of life.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion:\u003c/strong\u003e This study yielded promising results and found that Urtica comp. gel was statistically more effective than standard of care in reducing the need for rescue care in patients undergoing radiotherapy. Patients also rate the appearance of their RD as significantly better when using Urtica comp and scored lower pain and itchiness on the VAS. These results highlight that Urtica comp. gel may be an effective treatment option against RD. This should be further tested in a larger clinical trial.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTrial Registration\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNCT03494205\u003c/p\u003e","manuscriptTitle":"Urtica comp. gel for prevention and therapy of radiation dermatitis An interdisciplinary, interprofessional phase II randomized controlled trial in patients with breast cancer","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-08-02 11:40:26","doi":"10.21203/rs.3.rs-4710982/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"c9cf6930-f280-412f-b2ec-7b1eb65875d1","owner":[],"postedDate":"August 2nd, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-11-11T16:38:48+00:00","versionOfRecord":[],"versionCreatedAt":"2024-08-02 11:40:26","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4710982","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4710982","identity":"rs-4710982","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}